Hostname: page-component-66d9dcfd78-4xr4l Total loading time: 0 Render date: 2026-08-08T10:54:35.338Z Has data issue: false hasContentIssue false
  • English
  • Français

Dose–response considerations in transdiagnostic antidepressant effects of lurasidone: response to Chen et al: commentary, Ghenciulescu & De Giorgi

Published online by Cambridge University Press:  27 February 2026

Ana Ghenciulescu  and
Riccardo De Giorgi Open the ORCID record for Riccardo De Giorgi [Opens in a new window]
Ana Ghenciulescu
Affiliation:
Department of Psychiatry, University of Oxford, Warneford Hospital, Oxford, UK
Riccardo De Giorgi*
Affiliation:
Department of Psychiatry, University of Oxford, Warneford Hospital, Oxford, UK Oxford Health NHS Foundation Trust, Warneford Hospital, Oxford, UK Department of Experimental Medicine, University of Salento, College ISUFI, Lecce, Italy
*
Correspondence: Riccardo De Giorgi. Email: riccardo.degiorgi@psych.ox.ac.uk
Get access Rights & Permissions [Opens in a new window]

Abstract

An abstract is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'

Keywords

Psychotic disorders/schizophreniaAntipsychoticsAntidepressantsMeta-analysisPsychopharmacology

Information

Type
Commentary
Information
The British Journal of Psychiatry , Volume 228 , Issue 5 , May 2026 , pp. 491 - 492
Check for updates
Copyright
© The Author(s), 2026. Published by Cambridge University Press on behalf of Royal College of Psychiatrists

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Article purchase

Temporarily unavailable

References

Chen, Y-CB, Liang, C-S, Tseng, P-T, Hsu, C-W. Transdiagnostic efficacy of lurasidone on depressive symptoms: systematic review and meta-analysis of randomised controlled trials: commentary. Br J Psychiatry 2026; 228: 379–80.CrossRefGoogle ScholarPubMed
Ghenciulescu, A, Pearse, A, Minichino, A, Sampogna, G, De Giorgi, R, Fiorillo, A. Transdiagnostic efficacy of lurasidone on depressive symptoms: systematic review and meta-analysis of randomised controlled trials. Br J Psychiatry 2025; 226: 1–10.Google Scholar
Leucht, S, Crippa, A, Siafis, S, Patel, MX, Orsini, N, Davis, JM. Dose–response meta-analysis of antipsychotic drugs for acute schizophrenia. Am J Psychiatry 2020; 177: 342–53.CrossRefGoogle ScholarPubMed
Kishi, T, Matsuda, Y, Sakuma, K, Okuya, M, Iwata, N. Factors associated with discontinuation in the drug and placebo groups of trials of second generation antipsychotics for acute schizophrenia: a meta-regression analysis: discontinuation in antipsychotic trials. J Psychiatr Res 2020; 130: 240–6.CrossRefGoogle ScholarPubMed
Potkin, SG, Keator, DB, Kesler-West, ML, Nguyen, DD, van Erp, TG, Mukherjee, J, et al. D2 receptor occupancy following lurasidone treatment in patients with schizophrenia or schizoaffective disorder. CNS Spectr 2014; 19: 176–81.CrossRefGoogle ScholarPubMed
Lan, M. 18F-DOPA PET to elucidate the antidepressant mechanism of lurasidone in bipolar disorder. Clinical Trials.gov, 13 Nov 2023. Available from: https://clinicaltrials.gov/study/NCT03902613.Google Scholar
Yildiz, A, Siafis, S, Mavridis, D, Vieta, E, Leucht, S. Comparative efficacy and tolerability of pharmacological interventions for acute bipolar depression in adults: a systematic review and network meta-analysis. Lancet Psychiatry 2023; 10: 693–705.CrossRefGoogle ScholarPubMed

This journal is not currently accepting new eletters.

eLetters

No eLetters have been published for this article.